{"id":20727,"date":"2023-11-08T16:07:48","date_gmt":"2023-11-08T16:07:48","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20727"},"modified":"2023-11-29T11:16:23","modified_gmt":"2023-11-29T11:16:23","slug":"bio-rad-extends-range-of-anti-idiotypic-antibodies-for-use-in-preclinical-and-clinical-drug-development","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/bio-rad-extends-range-of-anti-idiotypic-antibodies-for-use-in-preclinical-and-clinical-drug-development\/","title":{"rendered":"Bio-Rad extends range of anti-idiotypic antibodies for use in preclinical and clinical drug development"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Bio-Rad extends range of anti-idiotypic antibodies for use in preclinical and clinical drug development<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies. These ready-made antibodies are suitable for developing selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for dupilumab, evolocumab, ipilimumab, and secukinumab, and their biosimilars. <\/strong><\/p>\n

<\/p>\n

Dupilumab limits inflammatory immune responses by targeting IL-4Ra and is approved for treatment of severe atopic eczema. Bio-Rad\u2019s six new anti-dupilumab antibodies can be used to develop PK bridging ELISAs to measure free and total drug, or as a surrogate positive control or reference standard in ADA assays. The range includes two fully human IgG1 clones and four TrailBlazer Antibodies https:\/\/www.bio-rad-antibodies.com\/trailblazer-antibody-spytag-spycatcher.html<\/a>\u00a0 with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast switching to a bivalent Fab or a full-length Ig-like format within an hour.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Bio-Rad has also expanded its anti-ipilimumab and anti-secukinumab portfolio to become the first provider of antibodies specific to the drug-target complex, allowing the detection of bound drug. HRP-labeled TrailBlazer antibodies are also now available for evolocumab.<\/p>\n

\u201cBio-Rad\u2019s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,\u201d said Dr John Cardone, marketing manager, Custom Antibodies, Life Science Group, Bio-Rad. \u201cOur drug-target complex binders are unique to Bio-Rad, enabling researchers to detect drugs in the target-bound state, and all our anti-idiotypic antibodies are provided with in-depth data packages for reproducible results.\u201d<\/p>\n

These new anti-idiotypic antibodies are approved for in vitro research, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.<\/p>\n

To learn more about Bio-Rad\u2019s anti-idiotypic antibodies, visit: www.bio-rad-antibodies.com\/anti-idiotypic-antibody.html<\/a>.<\/p>\n

Digital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n

\n